UAE – Mubadala Investment Company (Mubadala) has signed an agreement with National Resilience Inc., a first-of-its-kind manufacturing and technology company, to bolster the life science industry in the United Arab Emirates (UAE).
Mubadala will establish a new manufacturing facility, in which Resilience will operate and manufacture biopharmaceutical-related products out of the United Arab Emirates, according to the terms of the agreement.
The strategic partnership will build on its ongoing efforts to advance the development of the UAE’s life sciences sector, build national capabilities and increase national drug security for better bio pharma-manufacturing capabilities in the region.
“The Abu Dhabi based facility will be the first Goods Manufacturing Practice (GMP) biopharma facility in the UAE as well as the first of its kind in the region to manufacture essential life sciences products for advanced biologics,” Mubadala informed in statement.
The Emirati state-owned holding company pointed out that the range of therapeutics will be used to treat complex diseases such as cancer, infectious diseases, and inflammatory and autoimmune disorders.
In addition, Mubadala will leverage existing capabilities of its portfolio advanced manufacturing company Strata Manufacturing (Strata) and UAE initiatives to advance the UAE’s life sciences ecosystem.
“The agreement with Resilience builds on Mubadala’s decade of world-class patient care and its breakthrough health and wellness solutions,” the Abu Dhabi sovereign investor said.
The partnership comes a couple of weeks after Mubadala Health and G42 Healthcare teamed up to revolutionize the regional healthcare landscape and deliver a new approach to personalised, patient-centric care.
The signing ceremony was presided over by Badr Al-Olama Executive Director, UAE Clusters at Mubadala and Rahul Singhvi, ScD, Chief Executive Officer of Resilience, in the presence of Musabbeh Al-Kaabi, Chief Executive Officer of UAE Investments at Mubadala.
Executive Director Badr Al-Olama said: “The agreement will play an instrumental role in establishing a state-of-the-art biopharma campus that will secure the region’s supply chain from Abu Dhabi.”
The collaboration will also support Resilience’s ambitious goals to expand its manufacturing network outside of North America as well as to ensure trusted, cutting-edge biopharmaceutical manufacturing capacity is available to support local, regional and global economies.
It is in line with the UAE’s industrial strategy, which identifies life sciences as a priority sector by inviting investors, industrialists, and companies to launch operations in the country and benefit from its tremendous growth.